Thus, significant reduction both in ADAMTS levels and in ADAMTS/TIMP-3 ratios under anti-TNF-α treatment may represent an important mechanism for preventing future development of joint damage in RA patients. This evidence concerns the gene TIMP3 and rheumatoid arthritis.